All of 15 cases VMAT plans are accepted to treat with pass rate of ≥ 95% for both MatriXX and Portal Dosimetry systems. The pass rate of Portal Dosimetry (98 ÷ 99.9%) is independent on the complex of VMAT plans and usually more than pass rate of MatriXX (95 ÷ 97%).

RTplanEVA has researched and developed succsessful. For each volumetric modulated arc therapy plan, RTplanEVA processed data in approx. 05 seconds, while manual evaluation plan method needed approx. 20 minutes and included significant human error.

VMAT-SIB in concurrent combination with chemotherapy is safe and high efficiency in mangament of advanced stage head and neck cancers in terms of overall survival and progression-free survival with acceptable acute and late toxicities but need to enroll many more patient to confirm these findings.